A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis

Qinghuang Chen, Ke Chen, Guijie Guo, Fang Li, Chao Chen, Song Wang, Grzegorz Nalepa, Shile Huang, Ji Long Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.

Original languageEnglish (US)
Article numbere111611
JournalPLoS One
Volume9
Issue number10
DOIs
StatePublished - Oct 31 2014

Fingerprint

Cyclin-Dependent Kinase 3
cyclin-dependent kinase
Cyclin-Dependent Kinases
carcinogenesis
Carcinogenesis
K562 Cells
Tumors
neoplasms
leukemia
Neoplasms
Cells
Phosphoric Monoester Hydrolases
Cell Survival
cell viability
Leukemia
Growth
Dual-Specificity Phosphatases
apoptosis
Apoptosis
cells

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chen, Q., Chen, K., Guo, G., Li, F., Chen, C., Wang, S., ... Chen, J. L. (2014). A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. PLoS One, 9(10), [e111611]. https://doi.org/10.1371/journal.pone.0111611

A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. / Chen, Qinghuang; Chen, Ke; Guo, Guijie; Li, Fang; Chen, Chao; Wang, Song; Nalepa, Grzegorz; Huang, Shile; Chen, Ji Long.

In: PLoS One, Vol. 9, No. 10, e111611, 31.10.2014.

Research output: Contribution to journalArticle

Chen, Q, Chen, K, Guo, G, Li, F, Chen, C, Wang, S, Nalepa, G, Huang, S & Chen, JL 2014, 'A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis', PLoS One, vol. 9, no. 10, e111611. https://doi.org/10.1371/journal.pone.0111611
Chen Q, Chen K, Guo G, Li F, Chen C, Wang S et al. A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. PLoS One. 2014 Oct 31;9(10). e111611. https://doi.org/10.1371/journal.pone.0111611
Chen, Qinghuang ; Chen, Ke ; Guo, Guijie ; Li, Fang ; Chen, Chao ; Wang, Song ; Nalepa, Grzegorz ; Huang, Shile ; Chen, Ji Long. / A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. In: PLoS One. 2014 ; Vol. 9, No. 10.
@article{f1a9dd993e3841599b79247173622e4e,
title = "A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis",
abstract = "CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.",
author = "Qinghuang Chen and Ke Chen and Guijie Guo and Fang Li and Chao Chen and Song Wang and Grzegorz Nalepa and Shile Huang and Chen, {Ji Long}",
year = "2014",
month = "10",
day = "31",
doi = "10.1371/journal.pone.0111611",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis

AU - Chen, Qinghuang

AU - Chen, Ke

AU - Guo, Guijie

AU - Li, Fang

AU - Chen, Chao

AU - Wang, Song

AU - Nalepa, Grzegorz

AU - Huang, Shile

AU - Chen, Ji Long

PY - 2014/10/31

Y1 - 2014/10/31

N2 - CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.

AB - CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84910002317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910002317&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0111611

DO - 10.1371/journal.pone.0111611

M3 - Article

C2 - 25360622

AN - SCOPUS:84910002317

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e111611

ER -